Q1 EPS Estimate for Fennec Pharmaceuticals Lifted by Analyst

Fennec Pharmaceuticals Inc. (TSE:FRX) – Research analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a report issued on Monday, March 10th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.20). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at $0.48 EPS, Q4 2025 earnings at $0.61 EPS and FY2026 earnings at $3.18 EPS.

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 3.9 %

TSE:FRX opened at C$9.48 on Thursday. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The firm has a market capitalization of C$182.82 million, a price-to-earnings ratio of -160.59 and a beta of 0.25. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$15.20. The business has a fifty day moving average price of C$9.21 and a 200-day moving average price of C$7.93.

Insider Transactions at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was bought at an average price of C$3.87 per share, with a total value of C$96,840.00. Insiders sold 21,186 shares of company stock worth $196,017 in the last three months. Corporate insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.